Equitable Holdings Weighs Buyback Before Corebridge Merger as Raymond James Lifts Target to $58

NEW YORK, April 16 —

Raymond James upgraded Equitable Holdings (NYSE: EQH) to Strong Buy from Market Perform this week with a $58 price target, citing the pending merger with Corebridge, while company management has separately signaled it is weighing a share repurchase program before the Corebridge deal closes, according to reporting from Stock Titan and TipRanks. The combination of an upgraded bull-case target and the prospect of shrinking the share count ahead of a combination that would create a reported $22 billion US insurance platform has injected fresh dispersion into an already split sell-side view, with at least one separate desk carrying a $31 target and Barclays maintaining a bearish stance.

Background

Equitable Holdings and Corebridge have been positioned by press coverage as combining into what Reuters characterized as a roughly $22 billion US insurance group, a scale move that consolidates two large life-and-annuity franchises. The deal has been presented to investors primarily as a scale and synergy story, with consensus framing the transaction as accretive over time as the combined entity rationalizes duplicative distribution, technology, and back-office functions.

Against that backdrop, management's signal that the company is weighing a stock repurchase before the merger closes is a departure from the conservative capital stance that typically precedes a large stock-or-mixed deal. The clearest public read-through comes from coverage in Stock Titan and TipRanks indicating the company is evaluating buybacks ahead of closing. Acquirers and merger-of-equals parties often pause repurchase activity during a merger review to preserve cash, protect deal optics, and avoid perceived signaling about relative value.

Separately, Halper Sadeh LLC disclosed an investigation into whether Equitable shareholders are receiving a fair price in the proposed transaction, according to a Business Wire release. Such investigations are routine during public-company mergers and do not themselves constitute evidence of wrongdoing, but they add a layer of procedural risk around the exchange ratio.

Analyst View

The sell-side on Equitable is fractured. Raymond James upgraded the shares to Strong Buy with a $58 price target, citing the merger outlook, per Investing.com and GuruFocus. That target sits effectively at the $57.50 consensus and implies roughly 38% upside from the current $41.98 level. Barclays has moved in the other direction with what MarketBeat summarized as a pessimistic forecast on the stock, and a separate desk carries a $31 target, which would imply downside of roughly 26% from spot.

The dispersion between the high and low published targets is unusually wide for a large-cap insurer. A spread of that magnitude typically reflects genuine disagreement about either the standalone run-rate earnings power of EQH, the appropriate deal exchange ratio, or the probability that the Corebridge merger closes on current terms. Consensus remains at roughly 37% implied upside on a $57.50 average target, but that average now spans views that diverge by close to the stock's entire market value.

What the Data Shows

The quantitative case on Equitable pivots on four data points. First, valuation: the shares trade at approximately 4.7x forward earnings, a level that prices in skepticism about forward earnings power rather than a typical life-insurance multiple. Second, the reported trailing-twelve-month revenue base is roughly $11.7bn, with an 11.3% gross margin and reported free cash flow of approximately negative $9.7bn on a trailing basis, a figure driven by insurance-accounting volatility rather than operating cash burn in the industrial sense. Third, earnings have missed consensus four quarters in a row: most recently $1.73 against $1.75 expected, then $1.48 against $1.61, $1.10 against $1.30, and $1.30 against $1.48. Fourth, insiders have reportedly sold roughly $1.9M of stock in the past week.

The pre-close buyback signal is the most informative piece of the set. If management believes the standalone equity is materially undervalued at $41.98, repurchasing shares before a stock-or-mixed close shrinks the EQH base that ultimately exchanges into the combined entity, effectively transferring prospective synergy value to legacy EQH holders. That implied view is not consistent with the $31 bear target, and it is directionally consistent with Raymond James at $58. The insider selling cuts in the opposite direction and is difficult to square with the buyback framing, though the dollar amount is small relative to the company's market capitalization and can reflect pre-scheduled 10b5-1 plans rather than fresh conviction.

Risks

The bear case is concrete. Four consecutive earnings misses point to either a run-rate earnings base the sell-side has been slow to mark down or a rate and equity-market backdrop pressuring variable annuity economics. A 4.7x forward multiple can compress further if 2026 earnings are revised lower, particularly if Quiver Quantitative's framing of refocusing on 2026 profitability headwinds proves correct. The reported $9.7bn negative trailing free cash flow figure, while largely an artifact of insurance-accounting movements, will weigh on any screen-driven capital allocator.

Deal-specific risk is also live. The Halper Sadeh investigation, even as a procedural matter, flags the possibility that the exchange ratio is revisited. A wider regulatory review, a shareholder vote outcome that forces repricing, or a delay in closing would remove the merger as a near-term catalyst and leave the stock trading on standalone fundamentals that have disappointed for four straight quarters.

The separate $31 target and Barclays' pessimistic stance effectively encode these risks. Whether they are pricing or fundamental concerns depends on how the merger ratio is ultimately negotiated. If the deal closes on current terms, the bear targets look like pricing risk. If terms are renegotiated lower for EQH holders, or if the transaction breaks, the fundamental concerns become operative.

Outlook

Equitable Holdings is trading as if the Corebridge merger is the binding constraint on valuation, and the company's apparent willingness to buy back stock ahead of close suggests management disagrees with that framing. A pre-close repurchase at $41.98 is most easily read as an implicit assertion that the merger ratio understates EQH's contribution to the combined entity. The contrary signal, insider selling of roughly $1.9M in the past week, is small in context but not irrelevant. With Raymond James at $58, Barclays bearish, and a separate desk at $31, the shares are likely to trade on each incremental data point around the deal structure rather than on quarterly earnings until closing conditions and exchange terms are clarified. For investors focused on insurance consolidation, the signal-to-noise on EQH is unusually rich, and the buyback decision, if formally announced, would be the clearest tell on how management values its own equity relative to the merger math.

Run the free Equitable Holdings, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why is Equitable Holdings considering a buyback before the Corebridge merger closes?

Reporting from Stock Titan and TipRanks indicates management is evaluating a repurchase program before the deal closes. A pre-close buyback would reduce EQH's share count at $41.98, which can alter the effective economics of a stock or mixed-consideration merger. No authorization has been formally disclosed in an SEC filing as of this writing.

What is Raymond James's thesis on the upgrade to Strong Buy at $58?

Raymond James cited the Corebridge merger outlook when it lifted the rating from Market Perform, per Investing.com and GuruFocus. At $58, the target is roughly 38% above the $41.98 spot price and about 14% above the $57.50 consensus. The note frames the combination as a scale transaction that lifts return on equity through synergies.

Why is there such a wide spread in analyst targets on EQH?

Published targets this week range from roughly $31 at one desk to $58 at Raymond James, with Barclays on the cautious side per MarketBeat. The disagreement turns on merger math: whether the exchange ratio and expected synergies are accretive to EQH holders or whether the combination dilutes them at a point when the standalone franchise is already trading at 4.7x forward earnings.

How large will the combined Equitable-Corebridge company be?

Reuters reported the merger would create a US insurance group valued at roughly $22bn, combining Equitable's variable annuity and retirement platform with the former AIG life-and-retirement business that Corebridge now operates.

Should investors be concerned about the reported negative free cash flow of $9.7bn?

Free cash flow reported under standard conventions is a poor standalone metric for life insurers because it captures reserve movements and separate-account transfers that do not reflect underlying cash economics. The figure deserves context rather than alarm; earnings quality, capital ratios, and statutory surplus are more meaningful indicators for this sector.